Developments in HIV Vaccine Research | 17 Jun 2024

Source: TH

Why in News?

Despite 4 decades of effort, traditional vaccine approaches have been unable to prevent HIV acquisition because the virus mutates rapidly and hides from the immune system.

• Experts believe that more sophisticated vaccine strategies will be necessary and that the research and development process will take some more time.

What is the Traditional Vaccine Approach against HIV?

• About: 
  • It refers to the development of vaccines that aim to prevent infection from the human immunodeficiency virus (HIV) using conventional methods such as inactivated or weakened forms of the virus, viral subunits, or other components that elicit an immune response. 
  • These approaches typically involve stimulating the body's immune system to recognize and attack HIV, thus preventing infection or reducing the severity of the disease.
    • It teaches the body to fight off new invaders. 
• Failure of Traditional Vaccine Approach Against HIV: This approach has failed for HIV due to the following reasons.
  • Lack of Natural Self-Defence in Body: Unlike other viruses, most of the human bodies don't build good defences against HIV on their own.
  • Rapid mutation: HIV has parts that mutate often, like a shape-shifter. Vaccines target these parts, but by the time the vaccine is ready, the virus has already changed its shape.
  • Extreme viral diversity: HIV has a vast pool of circulating variants, making it difficult to target all strains.
  • Complex immune response: A successful vaccine needs to stimulate both antibody and cellular immune responses against a rapidly changing virus.

What is the Progress in the Development of Effective HIV Vaccines?

• Broadly Neutralising Antibodies (bNAbs): It is a kind of antibody, which could neutralise a large number of circulating viral strains. 

• Germline Targeting Approach: It uses a series of vaccines to encourage the development and multiplication of specialised precursor B cells that have the make bnAbs.

  • It identifies and matures B-cells into bNAb-producing cells against HIV to neutralise a wide range of HIV strains.
• Other Vaccines:
  • N332-GT5 Immunogen: To train B cells to produce a different powerful antibody called BG18.
  • MPER-Targeting Vaccine: It targets a more stable region of the HIV envelope that doesn't mutate as frequently.

Read more: ART’s Intervention in HIV/AIDS Treatment, Human Immunodeficiency Virus, UNAIDS Report: Progress & Challenges in HIV/AIDS Fight